Improved pharmacodynamics of l-asparaginase-loaded in human red blood cells

To evaluate the modification of pharmacodynamic parameters induced by the administration of l-asparaginase loaded into red blood cells, 13 patients received a single dose of l-asparaginase internalised into the carrier. The enzyme was loaded using a reversible lysis-resealing process. The dose per patient ranged from 30 to 200 IU·kg−1. Considerable heterogeneity occurred between patients: the level of l-asparaginase circulating after 24 h represented 47% of the total injected dose as compared to 74.8% for red blood cells (RBCs). However, the half-life of the enzyme remaining in the circulation was very similar to that of the RBC carrier, i.e. 29 days and 27 days, respectively, compared with 8–24 h for the free enzyme. Sustained elimination of plasma l-asparagine occurred, the duration of which was dependent on the injected dose. A single injection of 30·IU·kg−1 was sufficient to eliminate plasma l-asparagine over 10 days. With 150–200 IU·kg−1 the elimination period was extended to 50 days. These data show that the use of RBCs as carriers of l-asparaginase greatly improves the pharmacodynamic parameters of the drug.

[1]  V. Wahn,et al.  Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism. , 1985, Pediatric research.

[2]  J. H. Kim,et al.  Inhibition of leukemias in man by L-asparaginase. , 1967, Cancer research.

[3]  J. Rochemont,et al.  A single-column amino acid analysis method which resolves hexosamines and several cysteine derivatives. , 1978, Analytical biochemistry.

[4]  C. Nicolau,et al.  Resealed red blood cells as a new blood transfusion product. , 1985, Bibliotheca haematologica.

[5]  M. Nesbit,et al.  L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group. , 1981, Cancer treatment reports.

[6]  D. Karnofsky,et al.  Toxicity of E. coli L‐asparaginase in man , 1970, Cancer.

[7]  C. Spurr,et al.  A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma , 1990, Investigational New Drugs.

[8]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Lewis,et al.  Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. , 1985, Biochemical pharmacology.

[10]  F. Davis,et al.  Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice. , 1982, Clinical and experimental immunology.

[11]  S. Updike,et al.  Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. , 1983, The Journal of laboratory and clinical medicine.

[12]  R. Handschumacher,et al.  Immunological responses to L-asparaginase. , 1971, The Journal of clinical investigation.

[13]  M. Laguerre,et al.  Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.

[14]  J. Holland,et al.  Biochemical and pharmacological studies with asparaginase in man. , 1970, Cancer research.

[15]  R. Handschumacher,et al.  Evaluation of L-asparagine metabolism in animals and man. , 1970, Cancer research.

[16]  N. Cheung,et al.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. , 1986, The American journal of pediatric hematology/oncology.